Hebei yanxi chemical co.,LTD.

    Country: Country China (Mainland)

    Business Type: Trading Company

    Premium supplierDiamond
    supplier

    qq

      x
    • Ms.faithe
    • Mr.peter
    • Mr.korol
    • Ms.nina
    • Ms.noa

  • Ms.xing
    Tel: +86 17531153977

  • Ms.faithe
    Tel: 86-18531123677

  • Mr.peter
    manager
    Tel: 86-17531190177

  • Mr.korol
    manager
    Tel: 86-18531159677

  • Ms.nina
    Tel: 86-17330022511

  • Ms.noa
    manager
    Tel: 86-13131137377

  • Mobile:+86-17531153977
  • Tel:+86 17531153977
  • Fax:
  • URL:https://en.yan-xi.com/
  • Province/state:hebei
  • City:xingtai
  • Street:Zhang zhe, guangzong county, xingtai city, hebei province
  • MaxCard:
Home > Products >  Factory supply nebivolol

Factory supply nebivolol CAS NO.99200-09-6

  • FOB Price: USD: 1.00-2.00 /Metric Ton Get Latest Price
  • Min.Order: 1 Metric Ton
  • Payment Terms: L/C,T/T,MoneyGram,Other
  • Available Specifications:

    1(1-5)Metric Ton1(10-20)Metric Ton

  • Product Details

Keywords

  • nebivolol
  • Nebilet Bystolic
  • naibiluoer

Quick Details

  • ProName: Factory supply nebivolol
  • CasNo: 99200-09-6
  • Molecular Formula: C22H25F2NO4
  • Appearance: White powder
  • Application: Nyprol, the general name of nyprol hyd...
  • DeliveryTime: 7-10 day
  • PackAge: 25 kg/barrels
  • Port: shagnhai china
  • ProductionCapacity: 500 Metric Ton/Week
  • Purity: 99%
  • Storage: Store in a cool, ventilated warehouse....
  • Transportation: sea transportation
  • LimitNum: 1 Metric Ton
  • density ratio: (water =1) : 1.06

Superiority

Hebei Yanxi Chemical Co., Ltd. is a professional research, development and production of lead acetate benzene acetamide enterprise backbone members by local well-known entrepreneurs and professional senior engineers in the party's "low carbon environmental protection safety smooth" call and support form, the bold innovation on traditional production equipment and technology, using "high temperature alkali type production method" and "plastic basin of crystallization technology, on the basis of reducing the product cost make the product quality to achieve the same industry leading level.In the company all staff's efforts, in shandong, henan province guangdong South America Europe the United States for decades in Mexico, Brazil, South Africa, Zimbabwe and other places set up several partners, quality inspection department in the company, under the close supervision of a production and sales in the form of "label", provide the fastest speed convenient service for users across the country.

In "advancing with The Times, and the city every day, with the advancement of" under the guidance of the core ideas, adhering to the "relying on scientific and technological innovation, the development of circular economy" of the enterprise purpose, established in the market, enhance strength, go the way of scientific and sustainable development of environmental protection, relying on the national technology research and development center, increasing spending on research and development based on the domestic market, expand the international market, manufacturing high quality products, sincere service society, toward a modern, ecology, science and technology of the domestic first-class, the world's advanced chemical enterprises

 

Details

1, Nebivolol is a strong and selective third generation beta blocker. The intensity of blocking beta 1 receptor is 290 times of beta 2 receptor, while that of bisoprolol is 26 times, atenolol is 15 times, and F Naylor is 1.9 times. Therefore, this product has higher selectivity and does not cause contraction of bronchial smooth muscle and vascular smooth muscle, and has no endogenous sympathetic activity.
 
2. The effect on cardiac function and hemodynamics: naenolol has no obvious negative inotropic action. On the contrary, it has a certain protective effect on cardiac function, which can reduce the preload of the heart, and the post cardiac load has no change or a slight decrease. After application of NBI, the ejection fraction of patients with heart failure increased, while pulmonary arterial pressure and pulmonary capillary pressure did not change significantly.
 
3, the impact of exercise tolerance: many beta blockers can affect exercise tolerance, while NBI has little effect on exercise tolerance. Both nenilol and atenolol could increase the output of stroke per stroke, but neniprol increased cardiac output and decreased the total peripheral vascular resistance significantly, but atenolol had no effect.
 
4. Vasodilator effect: nillol has an additional vasodilator effect, which is a distinct advantage from other beta blockers. The Levo - and dextral bodies of nenprolol have vasodilatation, but the vasodilator of the left - body is vascular endothelium - dependent, that is, its vasodilatation is played mainly by strengthening the role of nitric oxide. Nalbil has no adrenergic effect on alpha receptor blockade. When using alpha receptor agonist phenylephrine, it still has vasodilator effect.
 
5, the effect on metabolism: nexolol had no obvious adverse effects on metabolism, had no significant influence on blood glucose in patients with hypertension, and did not cause changes in serum total cholesterol, low density lipoprotein cholesterol, extremely low density lipoprotein cholesterol, high density lipoprotein cholesterol and apolipoprotein A1 and B. NBL has no significant effect on renal hemodynamics.
 
6, naiprolol can be used for a long period of time, and it can maintain the efficacy of antihypertensive for 3 consecutive years.
 
Hypertension is one of the most common cardiovascular diseases in the world today. Epidemiological studies show that at present, there are 600 million hypertension patients worldwide, the prevalence rate of hypertension is about 10%, and that of some developed countries in Europe and the United States is 20%. The prevalence rate of hypertension in China is about 12%, and the number of hypertension patients is more than 100 million, with an annual growth rate of 3 million.
 
At present, sales of cardiovascular and cerebrovascular drugs account for 15% of total drug sales, up from about 20% in 80s. The increase in the number of patients with cardiovascular disease is driving the development of this market. According to the Research Report of market research firm Kalorama Information, the cardiovascular market will exceed US $100 billion by 2008. Over the years, beta blockers have been used to fight myocardial ischemia, antiarrhythmic and antihypertensive drugs.
 
In recent years, the market share of beta blockers has risen. According to hospital drug data, the market share of beta blockers in 2005 was 4.61%, and the market share rose to 5.06% in the first 3 quarters of 2006.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog